Copyright
©The Author(s) 2021.
World J Clin Cases. Oct 16, 2021; 9(29): 8694-8701
Published online Oct 16, 2021. doi: 10.12998/wjcc.v9.i29.8694
Published online Oct 16, 2021. doi: 10.12998/wjcc.v9.i29.8694
Group | n | PCT (ug/L) | CRP (mg/L) | WBC (× 109/L) | NE (%) |
Before treatment | |||||
Study | 37 | 12.89 ± 3.96 | 19.62 ± 6.44 | 20.61 ± 6.38 | 86.14 ± 7.21 |
Control | 37 | 14.05 ± 4.11 | 18.79 ± 5.96 | 21.21 ± 5.59 | 84.39 ± 6.95 |
t | 1.236 | 0.575 | 0.430 | 1.063 | |
P value | 0.220 | 0.567 | 0.668 | 0.291 | |
After 7 d of treatment | |||||
Study | 37 | 2.01 ± 0.56 | 3.11 ± 1.02 | 5.10 ± 1.83 | 56.35 ± 7.17 |
Control | 37 | 3.29 ± 0.64 | 5.67 ± 1.23 | 8.13 ± 3.01 | 64.22 ± 8.08 |
t | 9.155 | 9.745 | 5.232 | 4.432 | |
P value | < 0.001 | < 0.001 | < 0.001 | < 0.001 |
- Citation: Wang XX, Ma CT, Jiang YX, Ge YJ, Liu FY, Xu WG. Cefoperazone sodium/sulbactam sodium vs piperacillin sodium/tazobactam sodium for treatment of respiratory tract infection in elderly patients. World J Clin Cases 2021; 9(29): 8694-8701
- URL: https://www.wjgnet.com/2307-8960/full/v9/i29/8694.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v9.i29.8694